http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2881389-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c5073a0063d6be9e25c14d2af0a1ee89 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1d7e470e09803bd6bf24b2fd176109dd http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2013-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e42cd8e9b9ee52dd2f6f99ae5fd756a2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e55ba4ab0882e78e6eab304948b593dc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_579f46cecc309103936cb858141b45fc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c554fa53185939c270778df239745f10 |
| publicationDate | 2014-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2881389-A1 |
| titleOfInvention | Methods and kits for screening patients with a cancer |
| abstract | A method for screening patients with a cancer comprising i) determining in a tumor sample obtained from a patient an expression level ELA1 - ELAn of one or several genes GA1 - GAn representative of human adaptive immune response and an expression level ELI1 - ELIn of one or several genes Gl1 - GIn representative of human immunosuppressive response, ii) comparing the expression levels ELA1 - ELAn and ELI1 - ELIn determined at step i) with predetermined reference values ELRA1 - ELRAn and ELRI1 - ELRIn selected such as said predetermined reference values separate a panel of patients with a cancer into two groupings according to the expression level of said genes and to survival of patients according to Kaplan Meier curves analyses and associated logrank p values iii) concluding whether the patient has a good (level higher than the predetermined reference value) or a bad (level lower than the predetermined reference value) adaptive immune response and a good or a bad immunosuppressive response, optionally further comprising a step of concluding that a patient would or would not advantageously receive an antitumoral treatment, a kit comprising components for implementing step i) and a chemotherapeutic agent, an immunotherapeutic agent or a radiotherapeutic agent for use in the treatment of a cancer patient who is considered as responder to antitumoral treatment according to the method. |
| priorityDate | 2012-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 687.